RICHMOND, Va., July 2, 2012 /PRNewswire/ -- avVaa World Health Care Products, Inc. ("avVaa" or "the Company") (Pink Sheets: AVVH) Today, avVaa announced a distribution agreement with Eyedot Services Inc. to supply NEUROSKIN branded products to Canadian Retail Drugstores beginning in July. NEUROSKIN is a natural, mineral-based treatment for many skin conditions such as acne, psoriasis and itching.
"We are very excited about the opportunity to introduce NEUROSKIN to Canadian Drugstores," stated Ian Grantham, CEO of Eyedot Services Inc. "We will feature NEUROSKIN Rejuvenate plus 3 additional skin products to Canadian Drugstores initially targeting 6 stores in Western Canada; however we plan to expand throughout all of our Canadian Drugstores."
NEUROSKIN Rejuvenate will be available on store shelves to provide relief from common summer sunburns. This all natural topical spray promotes healing by quickly alleviating the discomfort, itching and pain associated with most abrasions, burns and skin irritations. With application, it lubricates, cools and soothes the skin. Additional NEUROSKIN products will also be available for the treatment of psoriasis, acne and itching.
"We have entered uncharted territory for avVaa as this is the first time NEUROSKIN has been on the shelves in a physical retail store," said Jason Price, President and COO. "This partnership represents another major step for avVaa in increasing our brand awareness and will ultimately launch the company into continued growth for our shareholders taking us from limited internet-based sales to the retail space."
NEUROSKIN is the second major product launch this year and represents avVaa's dedication to natural, effective products that are effective to the consumer and profitable to current investors. Unlike many competitors, NEUROSKIN does not contain cortisone, antibiotics, steroids or other unnatural ingredients or additives. The formula is non-greasy and odorless, does not stain clothing, and is easy to use.
About avVaa World Health Care Products, Inc.
avVaa is a global biotechnology company that specializes in effective, natural, therapeutic skin care products that improve quality of life and wellbeing for consumers. avVaa's patented European skin care formulas are scientifically registered and NHP-compliant. The formulas were developed to relieve and treat the symptoms of common skin ailments, including eczema, psoriasis and acne. avVaa is poised to manufacture and market its OTC Neuroskin® line of skin care products through mass food and drug channels in the United States and globally. The Company's secondary line of equine and pet care related products are already being distributed throughout all of Canada. For more information, visit: www.avvaa.com.
Jason Price President & Chief Operating Officer avVaa World Health Care Products, Inc. Phone: 1-866-864-6598; Fax: 1-866-789-9336
Safe Harbor: This news release contains statements which may constitute "forward‐looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of avVaa World Health Care Products, and members of its management, as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward‐looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward‐looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward‐statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before‐mentioned transactions. The Company undertakes no obligation to update or revise forward‐looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results. Potential risks and uncertainties include, but are not limited to, the ability to procure, properly price, retain, and successfully complete projects, the availability of technical personnel, changes in technology, and competition.
SOURCE avVaa World Health Care Products, Inc.